Sopharma AD-Sofia (WAR:SPH) ROCE %: 23.05% (As of Mar. 2026)


WAR:SPH Sopharma AD-Sofia WAR:SPH
67 GF Score
Price zł7.92
GF Value zł13.56
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia ROCE %?

Sopharma AD-Sofia WAR:SPH +8.49% 67 ROCE % is 23.05% as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.56 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sopharma AD-Sofia's annualized ROCE % for the quarter that ended in Mar. 2026 was 23.05%.

Sopharma AD-Sofia  (WAR:SPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sopharma AD-Sofia ROCE % Related Terms

Sopharma AD-Sofia ROCE % Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia ROCE % Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.15 10.83 14.19 10.84 16.91

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.21 14.64 17.24 10.59 23.05
WAR:SPH
67GF Score
Sopharma AD-Sofia WAR:SPH
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia ROCE % Calculation

Sopharma AD-Sofia's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=394.553/( ( (3520.24 - 1511.881) + (4553.599 - 1896.19) )/ 2 )
=394.553/( (2008.359+2657.409)/ 2 )
=394.553/2332.884
=16.91 %

Sopharma AD-Sofia's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=630.524/( ( (4553.599 - 1896.19) + (4553.874 - 1740.398) )/ 2 )
=630.524/( ( 2657.409 + 2813.476 )/ 2 )
=630.524/2735.4425
=23.05 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 23.05% mean?
Sopharma AD-Sofia (WAR:SPH) has a ROCE % of 23.05% as of Mar. 2026.
Is Sopharma AD-Sofia's ROCE % too high?
Sopharma AD-Sofia's current ROCE % is 23.05%. The Medical Distribution industry median ROCE % is 9.22. Sopharma AD-Sofia's value of 23.05% is 150% above this industry median. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's ROCE % compare to MCK and COR?
Sopharma AD-Sofia's ROCE % of 23.05% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.22. Sopharma AD-Sofia's value of 23.05% is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 9.22, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current ROCE % of 23.05% is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current ROCE % is 23.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.56, compared to a current price of zł7.92 — trading 41.6% below its estimated fair value. The current ROCE % is 23.05% and 150% above the Medical Distribution industry median of 9.22. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current ROCE % is 23.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.92 is trading 41.6% below its estimated GF Value™ of zł13.56. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

  • ROCE %: 23.05%
  • GF Value™: zł13.56 vs. price of zł7.92 (41.6% below fair value)
  • GF Score™: 67/100 with 3 warning signs
  • Industry Position: 150% above the Medical Distribution median

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score

Get the complete analysis for WAR:SPH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.92
Price
zł13.56
GF Value